Department of Neuroscience, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, Strada Le Grazie 8, 37134, Verona, Italy.
Department of Screening and Metabolic Diagnostics, Institute of Mother and Child, Warsaw, Poland.
Cell Mol Life Sci. 2022 May 20;79(6):305. doi: 10.1007/s00018-022-04343-w.
Aromatic amino acid decarboxylase (AADC) deficiency is a rare monogenic disease, often fatal in the first decade, causing severe intellectual disability, movement disorders and autonomic dysfunction. It is due to mutations in the gene coding for the AADC enzyme responsible for the synthesis of dopamine and serotonin. Using whole exome sequencing, we have identified a novel homozygous c.989C > T (p.Pro330Leu) variant of AADC causing AADC deficiency. Pro330 is part of an essential structural and functional element: the flexible catalytic loop suggested to cover the active site as a lid and properly position the catalytic residues. Our investigations provide evidence that Pro330 concurs in the achievement of an optimal catalytic competence. Through a combination of bioinformatic approaches, dynamic light scattering measurements, limited proteolysis experiments, spectroscopic and in solution analyses, we demonstrate that the substitution of Pro330 with Leu, although not determining gross conformational changes, results in an enzymatic species that is highly affected in catalysis with a decarboxylase catalytic efficiency decreased by 674- and 194-fold for the two aromatic substrates. This defect does not lead to active site structural disassembling, nor to the inability to bind the pyridoxal 5'-phosphate (PLP) cofactor. The molecular basis for the pathogenic effect of this variant is rather due to a mispositioning of the catalytically competent external aldimine intermediate, as corroborated by spectroscopic analyses and pH dependence of the kinetic parameters. Altogether, we determined the structural basis for the severity of the manifestation of AADC deficiency in this patient and discussed the rationale for a precision therapy.
芳香族氨基酸脱羧酶 (AADC) 缺乏症是一种罕见的单基因疾病,常在 10 岁前致命,导致严重的智力残疾、运动障碍和自主神经功能障碍。它是由于负责合成多巴胺和 5-羟色胺的 AADC 酶的基因发生突变引起的。通过全外显子组测序,我们发现了一种导致 AADC 缺乏症的新型纯合 c.989C>T (p.Pro330Leu) 变异体。Pro330 是一个重要的结构和功能元件的一部分:柔性催化环,被认为覆盖活性位点作为盖子,并正确定位催化残基。我们的研究提供了证据表明 Pro330 有助于实现最佳的催化能力。通过组合生物信息学方法、动态光散射测量、有限蛋白酶解实验、光谱和溶液分析,我们证明了 Pro330 被 Leu 取代,尽管不会导致明显的构象变化,但会导致酶的物种在催化中受到高度影响,两种芳香族底物的脱羧酶催化效率分别降低了 674 倍和 194 倍。这种缺陷不会导致活性位点结构的解体,也不会导致无法结合吡哆醛 5'-磷酸 (PLP) 辅酶。该变体致病效应的分子基础主要是由于催化能力外部亚胺中间体的定位错误,这得到了光谱分析和动力学参数的 pH 依赖性的证实。总之,我们确定了该患者 AADC 缺乏症表现严重程度的结构基础,并讨论了精准治疗的合理性。